Researchers at the Hebron Institute of Oncology Valley (VHIO) have developed a new treatment to inhibit a gene that causes the most tumors, including lung cancer, most aggressive. In Spain, 28,645 new cases of lung cancer have been reported every year and are the most common types of cancer in the world. The treatment has been tested by mice and, in 2020, they try to test the human phase.
Targeted group Laura Soucek, group researcher for tumor anti-tumor therapy VHIO and founder and CEO of Peptomyc SL, he found a new way of attack MYC, a the key in the development of most tumors. Souce began to develop the idea of prohibiting this gene 20 years ago. To do this, he designed this doctor Omomyc, A transgenic that inhibits this protein, which is created without harmful effect and now becomes an administering medication.
Dr. Laura Souce began 20 years ago to find ways to inhibit MYC, a key to the development of tumors.
As the magazine publishes Transitional Medicine of ScienceMarie-Eve Beaulieu, a former researcher at Soucek Group and currently a Peptomyc SL scientist, has shown that Omomyc can be used as anti-Myc therapy as a subtype for low-cell lung cancer. more aggressive and deadly among women and men.
Clinical trial in humans in 2020
Researcher Soucek the medicine confirms that the immune system has the ability to collect cells in the tumor vision. The doctor says that this effect on the immune system opens a new line of research by combining a new therapeutic strategy that demonstrates the potential of this MYC immunotherapy inhibitor with a great potential in different therapies.
Smoking is the main cause of most lung tumors, according to physicians.
Experts confirm this The main cause of most lung cancer is smoking. Every day, how many cigarettes you smoke and how much younger you start to consume, the greater your risk of developing lung cancer. Exposure to high levels of contamination, radiation and asbestos, among other things, may increase the risk of disease, even if the affected person is not a smoker.